Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment - Wikidata - awgldk - TriplyDB

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

http://www.wikidata.org/entity/Q26996793

about

Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Adipose tissue immunity and cancer Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.Human proangiogenic circulating hematopoietic stem and progenitor cells promote tumor growth in an orthotopic melanoma xenograft model.Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue Using Drosophila melanogaster to identify chemotherapy toxicity genes.Ramucirumab: preclinical research and clinical development.Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway Role of targeted agents in metastatic colorectal cancer.Complement inhibition in cancer therapy.Targeting tyrosine-kinases in ovarian cancer.Understanding and targeting resistance to anti-angiogenic therapies.VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update.Clinical experience with ramucirumab : outcomes in breast cancer.Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy.Revision of the concept of anti-angiogenesis and its applications in tumor treatment.

P2860

Q26752752-243D72CC-9E90-4F4C-8D96-5DF354304176 Q26862654-6A81C0ED-EE51-426A-8A61-E8A41BA298CB Q27001560-DA869DC6-52DC-4BCF-8442-D4C1E988302A Q33418595-FD83E918-71E6-4500-8D1C-9244422ECA13 Q34026969-5D65E7F5-310F-4B56-A3BD-4D14215B4CB4 Q34158325-61FF13DC-34A9-4771-89E7-27800B0BBFAC Q34242959-AC6BB9D5-0BBD-4CED-9FF8-567DE4411F5B Q34446310-302C0AED-9BEF-441C-817C-2597F240CDCD Q35678431-13424661-F586-4009-A66E-CB5472D9BC15 Q35826391-BDB4F728-6790-4AE8-8D06-9AE14421C5A2 Q36237852-9B555EF2-BD91-4EAC-8E19-1541A1FD2892 Q37604560-E708E51F-0958-494A-A81F-805158B43C6A Q38104294-928CC91C-B5CE-4AAC-9E77-461B795BB7A7 Q38109340-A9CFCB71-535E-4D1B-81FF-E9911F0672A9 Q38118388-99F39838-AC5B-426C-8AA8-EF02199C7E70 Q38133568-E45A4E36-95FF-476A-8B62-9B8D354995C3 Q38148602-F844CCBD-6FF3-447A-9E90-4DA17DE74EBE Q38228982-B5AD60F3-D3FE-4304-B83C-931CE5A60339 Q41764396-4D6BC356-8314-436D-B427-DA8254BAEA1C Q49852158-68046838-66EE-49D7-BBB5-4863C76781BA Q52904940-E83817C1-FD60-4C74-83CD-B518D5BD44C6

P2860

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

http://www.wikidata.org/entity/Q26996793

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@ast

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@en

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@nl

type

label

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@ast

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@en

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@nl

prefLabel

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@ast

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@en

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@nl

P1433

Q26996793-1DDF4088-02D7-46E6-A726-DDD2F0B22CEF

P1476

Q26996793-0E9B4411-DB8B-4D90-AF6C-17DC7923DD89

P2093

Q26996793-1D5433FA-A26F-45A3-AC40-35FA0B7E4AE4

Q26996793-820E3AA9-80E2-4DC6-AC23-B91EFE7E263A

Q26996793-FF1618B2-3AFB-4647-821A-93B401F5E5BC

P2860

Q26996793-130ED6EE-A7DF-4950-9FA0-661E82197F94

Q26996793-16DE76B5-B5C3-4F9C-A431-4E260948F6CD

Q26996793-21A228F8-05FD-4DAA-8443-F8159BA7366D

Q26996793-221CDA6E-47D8-4A1B-BCC1-E6B8410A5F47

Q26996793-3303B158-BFD9-4850-BEDB-D6452CCB96AF

Q26996793-384F0115-4470-43D2-BBB7-48D02E44792A

Q26996793-416A9E34-81C2-4FC9-A00C-F762FDA14190

Q26996793-43000F97-2021-4D6C-8492-BE48F187F6F9

Q26996793-54EA8242-5161-402E-8263-C1EDAB103E38

Q26996793-56353E5A-C1B3-400D-9C18-DBCC8A29EE69

P304

Q26996793-BC0757E3-B2A1-4355-80D5-128D36A199F9

P31

Q26996793-374B6FBC-50C1-4A66-BEAA-4DA3B590C9B8

P3181

Q26996793-6B70F006-EC7F-43A3-9114-9E6EBD43270D

P356

Q26996793-CDB068E8-0785-4132-9585-67F32A39AB51

P407

Q26996793-77995E96-9244-4565-9660-C04E92E8E68F

P433

Q26996793-811A8BEE-3AEA-4D0A-8621-CD4536A2A3BE

P478

Q26996793-975B1723-3E93-4DAA-9916-7FB9B0D441E4

P577

Q26996793-4FDFE672-55E7-4102-BB3A-C1BFB0500EFA

P698

Q26996793-22B49513-F31F-4B66-80C5-B161FAA5E5A5

P921

Q26996793-4C481486-F6C0-4609-82C4-81216FB7F2CF

P932

Q26996793-1ED22B0B-9CC2-41A2-A9FC-C3C92AF131D9

P3181

P356

S1470-2045(12)70275-9

P1433

The Lancet Oncology

P1476

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

@en

P2093

Bryan P Schneider

http://www.w3.org/2001/XMLSchema#string

Fei Shen

http://www.w3.org/2001/XMLSchema#string

Kathy D Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Tumor angiogenesis

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.

P304

e427-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2042731

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S1470-2045(12)70275-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23026828

http://www.w3.org/2001/XMLSchema#string

P921

P932

3730288

http://www.w3.org/2001/XMLSchema#string